johnson & johnson news

Johnson & Johnson Gets FDA Priority Review of Nipocalimab

J&J gets Priority Review designation for nipocalimab BLA

Johnson & Johnson (NYSE:JNJ) has received Priority Review designation from the FDA for the Biologics License Application for its drug nipocalimab in the treatment of antibody-positive patients with generalized myasthenia gravis.

Business Insider · 1d

Johnson & Johnson reports nipocalimab granted FDA Priority Review

Johnson & Johnson announced the nipocalimab Biologics License Application received Priority Review designation from the U.S Food and Drug

MarketWatch · 1d

Johnson & Johnson Gets FDA Priority Review of Nipocalimab in Generalized Myasthenia Gravis

Johnson & Johnson has won Food and Drug Administration priority review for its application seeking approval of nipocalimab in certain patients with generalized myasthenia gravis.

No. 2 South Carolina takes on Texas A&M

Associated Press · 1d

No. 2 South Carolina takes on Texas A&M following Johnson’s 22-point performance

No. 2 South Carolina plays the Texas A&M Aggies after Tessa Johnson scored 22 points in South Carolina's 95-68 victory over the Mississippi State Bulldogs.

Yahoo! Sports · 5h

No. 5 Alabama visits No. 10 Texas A&M after Phelps' 34-point performance

College Station, Texas; Saturday, 8 p.m. EST BOTTOM LINE: No. 10 Texas A&M plays No. 5 Alabama after Zhuric Phelps scored 34 points in Texas A&M's 80-78 win over the Oklahoma Sooners. The Aggies are 8-0 in home games.

The Charlotte Observer on MSN · 14h

No. 2 South Carolina WBB wins big against Texas A&M. Three quick observations

South Carolina breezed to a 90-49 win on Thursday night over Texas A&M. The victory moves the No. 2 Gamecocks to 15-1 on the year and improves their early tally in SEC play to 3-0. South Carolina is now 13-4 all time against the Aggies and has won 13 of the last 14 matchups.

Ben Johnson to interview with Patriots Fri.

USA TODAY Touchdown Wire o… · 1d

Ben Johnson's interview date for Patriots head coaching job revealed

Detroit Lions offensive coordinator Ben Johnson is scheduled to interview on Friday for the New England Patriots head coaching job. ESPN’s Adam Schefter reported the news on Wednesday. Johnson's offense in Detroit was the No.

NBC Sports on MSN · 1d

Ben Johnson to interview with Patriots Friday

Lions offensive coordinator Ben Johnson doesn't have a game this weekend, so he'll take some time to interview for head coaching opportunities.

Bleacher Report · 1d

NFL Rumors: Lions' Ben Johnson Scheduled to Interview with Raiders, Patriots, More

Detroit Lions offensive coordinator Ben Johnson is arguably the most coveted head coaching candidate on the market, and he's reportedly chosen four teams

Cautious Outlook on Johnson & Johnson Amid Currency and Legal Challenges

Wells Fargo analyst Larry Biegelsen maintained a Hold rating on Johnson & Johnson (JNJ – Research Report) yesterday and set a price target ...

GlobalData on MSN1d

Johnson & Johnson MedTech pauses Varipulse rollout in US

Despite the pause, the company clarified that the suspension does not impact commercial activity outside the US.

Dividend Roundup: Why I Prefer Johnson & Johnson Over Pfizer

Johnson & Johnson offers safer payouts and stronger growth. Discover why JNJ stock is the better dividend option compared to ...

Hold Recommendation for Johnson & Johnson Amid Promising Drug Trials and Regulatory Challenges

Analyst Terence Flynn from Morgan Stanley maintained a Hold rating on Johnson & Johnson (JNJ – Research Report) and keeping the price ...

21h

Johnson & Johnson Pauses US Varipulse Procedures Amid Safety Review, Investigates Brain-Related Events

Johnson & Johnson pauses U.S. Varipulse cases to investigate neurovascular events. The FDA-approved device integrates PFA therapy and 3D mapping for AFib treatment.

STAT2d

Johnson & Johnson says its lung cancer drug significantly extended survival

Johnson & Johnson says its bispecific antibody, paired with a Janssen drug, could change treatment for non-small lung cancer ...

Johnson & Johnson price target lowered to $160 from $177 at Bernstein

Bernstein lowered the firm’s price target on Johnson & Johnson to $160 from $177 and keeps a Market Perform rating on the shares as part of ...

Johnson & Johnson: A Potential Beneficiary Of A Great Rotation

JNJ has an attractive 3.41% dividend yield comparable to the yield on long-term bonds. Given the lack of price movement and ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

Johnson & Johnson Gets FDA Priority Review of Nipocalimab

No. 2 South Carolina takes on Texas A&M

Ben Johnson to interview with Patriots Fri.

Related topics